Clinigen has made its second significant acquisition in a matter of months, adding Link Healthcare for up to £100m. This is part of a plan to rapidly scale up the Group’s global footprint and puts it at the vanguard of providing access to medicines for patients with unmet clinical needs. We upgrade our EPS forecasts by 3-6% and increase our TP to 827p. Our 3yr CAGR in EPS is now 20%.
